7 commenti

  1. Outcome measure Evidence Implications Disease-oriented evidence Increase in intravaginal ejaculatory latency time Substantial Dapoxetine is consistently better than placebo at significantly increasing intravaginal ejaculatory latency time Patient-oriented evidence Perceived improvement in control over ejaculation Clear Dapoxetine is better than placebo at giving men greater perceived control over ejaculation Greater satisfaction with sexual intercourse Clear Dapoxetine gives patients greater satisfaction with intercourse compared with placebo Less personal distress related to ejaculation Clear Distress ratings are significantly reduced with dapoxetine compared with placebo Less interpersonal difficulty related to ejaculation Clear Significantly reduced ratings for interpersonal difficulty with dapoxetine compared with placebo Improved clinical global impression of change in premature ejaculation Clear More patients who received dapoxetine reported a positive change in premature ejaculation compared with those who received placebo Economic evidence On-demand use of dapoxetine is more cost-effective than long-term once-daily use of other selective serotonin reuptake inhibitors for treatment of premature ejaculation No evidence Health economics studies are needed On-demand use of dapoxetine is more cost-effective than psychotherapy No evidence Health economics studies are needed priligy and viagra combination

Lascia un commento

Il tuo indirizzo email non sarà pubblicato.